Balaji Amines Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.
Published 24 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹6.9K Cr
The company targets around 25% to 30% volume growth by end of FY27 compared to current levels. Management expects 20% to 30% volume growth in the coming financial year (FY27), driven by new plants such as Dimethyl Ether (DME), Acetonitrile, and N-Methyl Morpholine (NMM), as well as increased demand from battery industries.
From Balaji Amines Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,078
Market Cap
₹6.9K Cr
P/E Ratio
33.9
How does Balaji Amines Ltd rank in Chemicals & Petrochemicals?
Compare Balaji Amines Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Balaji Amines Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →The company targets around 25% to 30% volume growth by end of FY27 compared to current levels.
- →For the current year, a conservative volume growth of 10% to 15% is expected.
- →Growth drivers include new products: Dimethyl Ether (DME), Acetonitrile (ACN), and N-Methyl Morpholine (NMM).
- →DME plant commissioning expected in Q1 FY27, with utilization likely at 30%-40% in the current year and up to 80%-90% in coming years.
- →Balaji Specialty Chemicals subsidiary is investing significantly, with INR 350-400 crores capex planned in phase 1, supporting expansion.
- →Revenue target of INR 3,000 crores by FY28, supported by expanded specialty product portfolio and DME.
- →EBITDA margins are expected to be sustainable between 22%-23% alongside volume growth.
- →Continuous ramp-up expected as battery industries and other end markets stabilize, supporting further volume increases.
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
🏗️ Capital Expenditure Plans
Yes- →Standalone capex for FY27: Around INR 20 crores balance for 3 products (DME, NMM, ACN), mostly already paid for equipment.
- →Balaji Specialty Chemicals subsidiary: Total Phase 1 capex INR 750 crores; INR 350-400 crores planned. For FY27, >INR 100 crores already spent, plus another INR 200-250 crores expected.
- →Greenfield and brownfield expansions ongoing; Phase 1 for greenfield partially in production (ethylamine, DMC) with modifications underway for specialty chemicals plant.
- →Dimethyl Ether (DME) plant: Commissioning expected in Q1 FY27, pending road transportation permission; capacity ramp-up projected reaching 50-60% by FY27-end, 80-90% in subsequent years.
- →Capex combined on consolidated basis for FY27 estimated between INR 275-290 crores.
- →Management inviting investors soon to visit plants to witness ongoing expansions.
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
📋 Order Book & Pipeline
No information- →The company is in the process of expanding its product range with new products such as Dimethyl Ether (DME), Acetonitrile, and N-Methylmorpholine (NMM).
- →For DME, the plant is commissioned but awaiting road transport permission; production is ongoing, and once permission is granted, utilization is expected to increase to 30-40% in the current year and up to 80-90% in later years.
- →Prospective customers for DME have been approached, and trial shipments with 500 kg cylinders are underway to secure bulk orders.
- →Some battery chemical products have received commercial orders, but full-scale demand depends on battery manufacturers ramping up operations.
- →The greenfield and brownfield capex projects (e.g., Balaji Specialty Chemicals) are ongoing, with modifications progressing and investor plant visits planned soon.
- →No specific numeric order book or pending orders disclosed, but the company indicated growing demand and upcoming volume growth of 20-30% driven by new products and markets.
Key Metrics
1 of 5 growth signals positive in the Q4 FY26 call.
Revenue
Margin
Capex
Fundraise
Order Book
How does Balaji Amines Ltd rank vs peers in Chemicals & Petrochemicals?
Pro featureSee full Chemicals & Petrochemicals sector rankings
Continue your research
What Balaji Amines Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- NOCIL (Q4 FY26)
The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…
- Indo Borax & Chemicals Ltd (Q4 FY26)
175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…
- ROSSARI (Q4 FY26)
50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…
- PIDILITIND (Q4 FY26)
Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…
Frequently Asked Questions
What were Balaji Amines Ltd Q4 FY26 results?
The company targets around 25% to 30% volume growth by end of FY27 compared to current levels. Management expects 20% to 30% volume growth in the coming financial year (FY27), driven by new plants such as Dimethyl Ether (DME), Acetonitrile, and N-Methyl Morpholine (NMM), as well as increased demand from battery industries.
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 33.9 with a market cap of ₹6,914 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Standalone capex for FY27: Around INR 20 crores balance for 3 products (DME, NMM, ACN), mostly already paid for equipment.
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.